415 related articles for article (PubMed ID: 15000272)
1. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
Nyhlin H; Bang C; Elsborg L; Silvennoinen J; Holme I; Rüegg P; Jones J; Wagner A
Scand J Gastroenterol; 2004 Feb; 39(2):119-26. PubMed ID: 15000272
[TBL] [Abstract][Full Text] [Related]
2. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.
Kellow J; Lee OY; Chang FY; Thongsawat S; Mazlam MZ; Yuen H; Gwee KA; Bak YT; Jones J; Wagner A
Gut; 2003 May; 52(5):671-6. PubMed ID: 12692051
[TBL] [Abstract][Full Text] [Related]
3. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
[TBL] [Abstract][Full Text] [Related]
4. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
[TBL] [Abstract][Full Text] [Related]
5. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
Tegaserod Clinical Research Group
Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
[TBL] [Abstract][Full Text] [Related]
6. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
7. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H
Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040
[TBL] [Abstract][Full Text] [Related]
8. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
Reilly MC; Barghout V; McBurney CR; Niecko TE
Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
[TBL] [Abstract][Full Text] [Related]
9. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
10. Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care.
Layer P; Keller J; Mueller-Lissner S; Rüegg P; Loeffler H
Digestion; 2005; 71(4):238-44. PubMed ID: 16024929
[TBL] [Abstract][Full Text] [Related]
11. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
Kamm MA; Müller-Lissner S; Talley NJ; Tack J; Boeckxstaens G; Minushkin ON; Kalinin A; Dzieniszewski J; Haeck P; Fordham F; Hugot-Cournez S; Nault B
Am J Gastroenterol; 2005 Feb; 100(2):362-72. PubMed ID: 15667494
[TBL] [Abstract][Full Text] [Related]
12. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
[TBL] [Abstract][Full Text] [Related]
13. Review article: tegaserod for chronic constipation.
Johanson JF
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():20-4. PubMed ID: 15521851
[TBL] [Abstract][Full Text] [Related]
14. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.
Bardhan KD; Forbes A; Marsden CL; Mason T; Short G
Aliment Pharmacol Ther; 2004 Jul; 20(2):213-22. PubMed ID: 15233702
[TBL] [Abstract][Full Text] [Related]
15. Tegaserod for the treatment of irritable bowel syndrome.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M
Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724
[TBL] [Abstract][Full Text] [Related]
17. Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial.
Pace F; Maurano A; Ciacci C; Savarino V; Attili A; Iaquinto G; Magni E; Porro GB
Eur Rev Med Pharmacol Sci; 2010 Mar; 14(3):155-62. PubMed ID: 20391952
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
Fock KM; Wagner A;
J Gastroenterol Hepatol; 2007 Aug; 22(8):1190-8. PubMed ID: 17524039
[TBL] [Abstract][Full Text] [Related]
20. Review article: the safety profile of tegaserod.
Schoenfeld P
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
